The letter from a major shareholder of Nabi Pharmaceuticals Inc., attacking CEO Thomas McLain for the company's "abysmal" performance and "bargain-basement stock price," sent Nabi's shares up about 5 percent on the day it was made public last week, but the story may not be over. (BioWorld Today)